Incyte has been granted a patent for a compound that inhibits PI3K-?, useful in treating autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases. The compound is specifically defined as 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide or its salt. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Compound for treating autoimmune diseases, cancer, cardiovascular, and neurodegenerative diseases
A recently granted patent (Publication Number: US11926630B2) discloses a compound identified as 2-(3-(8-Amino-6-(trifluoromethyl)imidazo[1,2-a]pyrazin-3-yl)-4-methylphenyl)-3,3,3-trifluoro-2-hydroxypropanamide, or its pharmaceutically acceptable salt. This compound is claimed for its potential pharmaceutical applications.
Furthermore, the patent also covers a pharmaceutical composition that includes the aforementioned compound or its pharmaceutically acceptable salt, along with one or more pharmaceutically acceptable carriers. This composition is designed for use in the development of pharmaceutical products. The patent provides protection for the compound and its pharmaceutical composition, highlighting their potential significance in the field of medicine.
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.